Sunitinib Malate Market Forecast for Pancreatic Cancer, 2016-2017 - New Market Report

Sunitinib Malate Market Forecast for Pancreatic Cancer, 2016-2017, G7 Countries, (U.S., Germany, France, U.K., Italy, Spain, Japan

The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 million by 2021, at a CAGR of 13.9% from 2016 to 2021. The growing incidence of pancreatic cancer (especially pNET) and increasing adoption of sunitinib malate in patients with unrespectable, locally advanced, or metastatic pNET are the major factors driving the sunitinib malate market for pancreatic cancer in G7 Countries. The overall sunitinib malate market for pancreatic cancer in G7 countries is expected to witness double-digit growth in the coming years.

Full Report Details at
- http://www.fastmr.com/prod/1180303_sunitinib_malate_forecast_for.aspx?afid=301

This report covers the sunitinib malate market for pancreatic cancer in G7 countries-U.S., Germany, France, U.K., Italy, Spain, and Japan. The U.S. is expected to be the largest market for sunitinib malate (for pancreatic cancer) primarily due to the higher number of patients suffering from pancreatic cancer in the country. However, the market in the U.K. is expected to witness a higher growth rate during the forecast period.

The quantitative data in the forecasting model covers various level of analysis, such as epidemiology studies (overall pancreatic cancer incidence and five-year survival), number of drug-treated patients suffering from pancreatic cancer, number of drug-treated patients suffering from pancreatic neuroendocrine tumor (pNET), percentage of patients eligible for taking sunitinib malate, and pricing analysis of sunitinib malate in all G7 countries.

The market research data, current market size, and forecast provided in this report will help key players as well as new entrants to make necessary decisions regarding product offerings, changes in marketing approaches, and R&D investments for innovation in products. This report also provides qualitative assessment of pancreatic cancer, its stages, and approved drugs for pNET.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market. Analysis provided in the report will help these firms to stay competitive in the market and take strategic decisions on pipeline drugs for pancreatic cancer. Companies purchasing this report can use the below-mentioned information for strategy development, market penetration, and product development/innovation.

The report provides insights on the following pointers:

* Epidemiology of Pancreatic Cancer: This section provides the incidence and five-year survival of patients suffering from pancreatic cancer and its year-on-year growth.
* Penetration of Pancreatic Cancer Drugs: This section provides analysis regarding the penetration of drugs versus surgical procedures performed to treat pancreatic cancer.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape
- OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024
- Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence
- OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024
- EpiCast Report: Gastric Cancer - Epidemiology Forecast to 2024